Provided by Tiger Trade Technology Pte. Ltd.

Replimune Group Inc.

13.07
-0.3800-2.83%
Post-market: 13.200.1262+0.97%19:54 EDT
Volume:1.30M
Turnover:17.12M
Market Cap:1.23B
PE:-4.14
High:13.83
Open:13.69
Low:12.80
Close:13.45
52wk High:16.33
52wk Low:1.50
Shares:94.22M
Float Shares:77.49M
Volume Ratio:0.48
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1550
EPS(LYR):-3.3828
ROE:-134.29%
ROA:-51.30%
PB:11.66
PE(LYR):-3.86

Loading ...

US FDA Approves Replimune's Skin Cancer Drug

Reuters
·
Aug 07

Replimune Group - Approval Based on Objective Response Rate and Duration of Response; Confirmatory Trial Required

THOMSON REUTERS
·
Aug 07

Replimune Announces FDA Accelerated Approval of Tudriqevtm in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an Anti-Pd-1 Based Regimen

THOMSON REUTERS
·
Aug 07

Leerink Partners Upgrades Replimune Group to Outperform From Market Perform, Adjusts Price Target to $17 From $11

MT Newswires Live
·
Aug 04

Replimune Group Raised to Outperform from Market Perform by Leerink Partners

Dow Jones
·
Aug 04

Replimune Group Inc : Leerink Partners Raises to Outperform from Market Perform; Raises Target Price to $17.00 from $11.00

THOMSON REUTERS
·
Aug 04

Top Midday Gainers

MT Newswires Live
·
Aug 01

Apple, Amazon, Reddit, Micron, SK Hynix, Roblox, and More Stocks That Explain Today's Market

Dow Jones
·
Jul 31

Replimune Group Inc : Piper Sandler Raises to Overweight from Neutral; Raises Target Price to $14 from $9

THOMSON REUTERS
·
Jul 31

This Biotech Stock is Soaring 132% After Key FDA Vote on Skin Cancer Treatment

Dow Jones
·
Jul 31

Replimune Group Raised to Overweight from Neutral by Cantor Fitzgerald

Dow Jones
·
Jul 31

Top Premarket Gainers

MT Newswires Live
·
Jul 31

Wedbush Upgrades Replimune Group to Outperform From Neutral, Raises Price Target to $12 From $9

MT Newswires Live
·
Jul 31

Replimune Shares Take Flight Premarket After FDA Panel Backs RP1

Dow Jones
·
Jul 31

Replimune Shares More than Double to $11.75 Premarket After US FDA Advisers Back Co's Skin Cancer Drug

THOMSON REUTERS
·
Jul 31

Replimune RP1 Melanoma BLA Wins Favorable 10-3 FDA Advisory Panel Vote on Ignyte Efficacy Data

Reuters
·
Jul 31

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for Rp1 in Advanced Melanoma

THOMSON REUTERS
·
Jul 31

Replimune Group - FDA Target Action Date for Rp1 Bla Resubmission is August 2, 2026

THOMSON REUTERS
·
Jul 31

FDA panel votes 10-3 in favor of Replimune’s experimental melanoma treatment

TIPRANKS
·
Jul 31

FDA Panel Votes in Favor of Replimune's Melanoma Treatment

Dow Jones
·
Jul 31